News

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic…

2 years ago

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Trial Meets Both Primary and Key Secondary EndpointsLAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc.…

2 years ago

IRLAB Receives Grant from The Michael J. Fox Foundation to Support Development of IRL757 for the Treatment of Apathy

GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB Therapeutics…

2 years ago

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services…

2 years ago

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler…

2 years ago

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive…

2 years ago

BioAdaptives, Inc. to Form New Division, AI BodyShape Lab, to Promote Adult Fitness and Weight Management

BioAdaptives, Inc. BioAdaptives’ AI-based Fit Your Outfit app LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –…

2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…

2 years ago

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generationSAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE)…

2 years ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL);…

2 years ago